Quartet of COVID-19 Vaccine Candidates Head Toward the Homestretch

A trio of distinguished experts interviewed by GEN, and two investment firms that track biopharma stocks, agreed that three of the four candidates showed sufficient promise in Phase I or Phase I/II studies to warrant interest from researchers, industry observers, and others in upcoming trials